Please use this identifier to cite or link to this item:
|Title:||Inhibiting system xC− and glutathione biosynthesis – a potential Achilles' heel in mutant-p53 cancers|
|Authors:||Clemons, Nicholas J;Liu, David S;Duong, Cuong P;Phillips, Wayne A|
|Citation:||Molecular & Cellular Oncology 2017; 4(5): e1344757|
|Abstract:||Effective therapeutic strategies to target mutant tumor protein p53 (TP53, best known as p53) cancers remain an unmet medical need. We found that mutant p53 impairs the function of nuclear factor (erythroid-derived 2)-like 2 (NFE2L2, commonly known as NRF2), suppresses solute carrier family 7 member 11 (SLC7A11) expression, and diminishes cellular glutamate/cystine exchange. This decreases glutathione biosynthesis, resulting in redox imbalance. Mutant p53 tumors are thus inherently susceptible to further perturbations of the SLC7A11/glutathione axis.|
reactive oxygen species (ROS)
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.